Document Type : Original Article
Authors
1 Biotechnology Research Center, Shiraz University of Medical Sciences, Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
2 Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract
INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is caused by overactivation of
immune system. Gene mutations, infections, malignant, and autoimmune trigger the development
of the disease.
MATERIALS AND METHODS: Clinical data and peripheral blood samples of 21 patients suspected of
HLH were collected in Shiraz Medical Centers 2017–2018. Peripheral blood samples were analyzed
for soluble interleukin‑2 receptor alpha (sIL2Rα) marker (sCD25), and the results were compared
with 36 normal controls as well as comparison with clinical findings and other laboratory parameters.
RESULTS: Twenty‑one patients (11 males and 10 females) with an average age of 5.2 were
investigated. In this study, peripheral blood samples were taken from 16 newly diagnosed patients
before treatment, and five were posttreatment blood samples. The mean sIL2Rα level before
treatment in 16 patients was 9023 pg/ml. The mean peripheral blood sample of the 36 controls was
3025 pg/ml. The mean of the five posttreatment samples was 4198 pg/ml. Significant difference
between pretreatment and the control group was observed. However, no significant difference was
detected between after treatment samples and the control group. By comparing the sIL2Rα levels
between patients with increased aspartate aminotransaminase (AST) and patients with normal AST
level, there was a significant difference in the amount of IL2Rα level.
CONCLUSION: This study highlights the importance of IL2Rα marker in the diagnosis and follow‑up,
during treatment and suppression. Furthermore, a significant difference with respect to AST level
requires further investigation.
Keywords
lymphohistiocytosis: Advances in pathophysiology, diagnosis,
and treatment. J Pediatr 2013;163:1253‑9.
2. Zhang L, Zhang S, Xu J, Hu Y, Wang L, Zhang X, et al. Significance
of soluble interleukin‑2 receptor in patients with hemophagocytic
lymphohistiocytosis. Leuk Lymphoma 2011;52:1360‑2.
3. Safaei A, Shokripour M, Omidifar N. Bone marrow and karyotype
findings of patients with pancytopenia in Southern Iran. Iran J
Med Sci 2014;39:333‑40.
4. Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH,
Imashuku S, et al. HLH‑2004: Diagnostic and therapeutic
guidelines for hemophagocytic lymphohistiocytosis. Pediatr
Blood Cancer 2007;48:124‑31.
5. Rivière S, Galicier L, Coppo P, Marzac C, Aumont C, Lambotte O,
et al. Reactive hemophagocytic syndrome in adults: Aretrospective
analysis of 162 patients. Am J Med 2014;127:1118‑25.
6. Emile JF, Abla O, Fraitag S, Horne A, Haroche J, Donadieu J,
et al. Revised classification of histiocytoses and neoplasms of the
macrophage‑dendritic cell lineages. Blood 2016;127:2672‑81.
7. Chen Y, Wang Z, Luo Z, Zhao N, Yang S, Tang Y. Comparison
of Th1/Th2 cytokine profiles between primary and secondary
haemophagocytic lymphohistiocytosis. Ital J Pediatr 2016;42:50.
8. Fardet L, Galicier L, Lambotte O, Marzac C, Aumont C,
Chahwan D, et al. Development and validation of the HScore, a
score for the diagnosis of reactive hemophagocytic syndrome.
Arthritis Rheumatol 2014;66:2613‑20.
9. Komp DM, McNamara J, Buckley P. Elevated soluble interleukin‑2
receptor in childhood hemophagocytic histiocytic syndromes.
Blood 1989;73:2128‑32.
10. Mellor‑Heineke S, Villanueva J, Jordan MB, Marsh R, Zhang K,
Bleesing JJ, et al. Elevated granzyme b in cytotoxic lymphocytes
is a signature of immune activation in hemophagocytic
lymphohistiocytosis. Front Immunol 2013;4:72.
11. Gao ZY, Li XY, Bhandari V, Li LD, Lan D. Pre‑B‑cell
colony‑enhancing factor is markedly elevated in childhood
hemophagocytic lymphohistiocytosis. Genet Mol Res
2015;14:5287‑95.
12. Hayden A, Lin M, Park S, Pudek M, Schneider M, Jordan MB,
et al. Soluble interleukin‑2 receptor is a sensitive diagnostic test
in adult HLH. Blood Adv 2017;1:2529‑34.
13. Yoon JH, Park KH, Yoon SY, Min GJ, Park SS, Jeon YW,
et al. Natural‑killer cell cytotoxicity and interleukin‑2R as a
relevant marker for diagnosis of secondary hemophagocytic
lymphohistiocytosis in adult patients: The results of prospective Phase II observational study. Am Soc Hematology 2018;
132 (Suppl 1) 4939.
14. Imashuku S, Ikushima S, Esumi N, Todo S, Saito M. Serum levels
of interferon‑gamma, cytotoxic factor and soluble interleukin‑2
receptor in childhood hemophagocytic syndromes. Leuk
Lymphoma 1991;3:287‑92.
15. Imashuku S, Hibi S, Sako M, Ishida Y, Mugishima H, Chen J,
et al. Soluble interleukin‑2 receptor: A useful prognostic factor
for patients with hemophagocytic lymphohistiocytosis. Blood
1995;86:4706‑7.
16. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT,
et al. The diagnostic significance of soluble CD163 and soluble
interleukin‑2 receptor alpha‑chain in macrophage activation
syndrome and untreated new‑onset systemic juvenile idiopathic
arthritis. Arthritis Rheum 2007;56:965‑71.
17. Debaugnies F, Mahadeb B, Ferster A, Meuleman N, Rozen L,
Demulder A, et al. Performances of the H‑score for diagnosis
of hemophagocytic lymphohistiocytosis in adult and pediatric
patients. Am J Clin Pathol 2016;145:862‑70.
18. Blázquez‑Gamero D, Domínguez‑Pinilla N, Chicharro C,
Negreira S, Galán P, Pérez‑Gorricho B, et al. Hemophagocytic
lymphohistiocytosis in children with visceral leishmaniasis.
Pediatr Infect Dis J 2015;34:667‑9.
19. Tothova Z, Berliner N. hemophagocytic syndrome and critical
illness: New insights into diagnosis and management. J Intensive
Care Med 2015;30:401‑12.
20. Yasumi T, Hori M, Hiejima E, Shibata H, Izawa K, Oda H,
et al. Laboratory parameters identify familial haemophagocytic
lymphohistiocytosis from other forms of paediatric
haemophagocytosis. Br J Haematol 2015;170:532‑8.
)